Format
Sort by

Send to

Choose Destination

Search results

Items: 16

1.

Production of CGMP-Grade Lentiviral Vectors.

Ausubel LJ, Hall C, Sharma A, Shakeley R, Lopez P, Quezada V, Couture S, Laderman K, McMahon R, Huang P, Hsu D, Couture L.

Bioprocess Int. 2012 Feb;10(2):32-43. No abstract available.

2.

GMP scale-up and banking of pluripotent stem cells for cellular therapy applications.

Ausubel LJ, Lopez PM, Couture LA.

Methods Mol Biol. 2011;767:147-59. doi: 10.1007/978-1-61779-201-4_11.

PMID:
21822873
3.

Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment.

Ausubel LJ, Meseck M, Derecho I, Lopez P, Knoblauch C, McMahon R, Anderson J, Dunphy N, Quezada V, Khan R, Huang P, Dang W, Luo M, Hsu D, Woo SL, Couture L.

Hum Gene Ther. 2011 Apr;22(4):489-97. doi: 10.1089/hum.2010.159.

4.

Functional and molecular comparison of anergic and regulatory T lymphocytes.

Knoechel B, Lohr J, Zhu S, Wong L, Hu D, Ausubel L, Abbas AK.

J Immunol. 2006 Jun 1;176(11):6473-83.

5.

Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.

Cooper LJ, Ausubel L, Gutierrez M, Stephan S, Shakeley R, Olivares S, Serrano LM, Burton L, Jensen MC, Forman SJ, DiGiusto DL.

Cytotherapy. 2006;8(2):105-17.

PMID:
16698684
6.

Characterization of in vivo expanded OspA-specific human T-cell clones.

Ausubel LJ, O'Connor KC, Baecher-Allen C, Trollmo C, Kessler B, Hekking B, Merritt D, Meyer AL, Kwok B, Ploegh H, Huber BT, Hafler DA.

Clin Immunol. 2005 Jun;115(3):313-22.

PMID:
15893699
7.

Functional tolerance is maintained despite proliferation of CD4 T cells after encounter with tissue-derived antigen.

Ausubel LJ, Chodos A, Bekarian N, Abbas AK, Walker LS.

Dev Immunol. 2002 Sep;9(3):173-6.

8.

CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen.

Walker LS, Ausubel LJ, Chodos A, Bekarian N, Abbas AK.

J Immunol. 2002 Dec 1;169(11):6202-9.

9.

The roles of CD28 and CD40 ligand in T cell activation and tolerance.

Howland KC, Ausubel LJ, London CA, Abbas AK.

J Immunol. 2000 May 1;164(9):4465-70.

10.

Cross-reactivity of T-cell clones specific for altered peptide ligands of myelin basic protein.

Ausubel LJ, Bieganowska KD, Hafler DA.

Cell Immunol. 1999 Apr 10;193(1):99-107.

PMID:
10202117
11.

Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99.

Ausubel LJ, Krieger JI, Hafler DA.

J Immunol. 1997 Sep 1;159(5):2502-12.

PMID:
9278344
12.

Weak peptide agonists reveal functional differences in B7-1 and B7-2 costimulation of human T cell clones.

Anderson DE, Ausubel LJ, Krieger J, Höllsberg P, Freeman GJ, Hafler DA.

J Immunol. 1997 Aug 15;159(4):1669-75.

PMID:
9257827
13.

Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease.

Bieganowska KD, Ausubel LJ, Modabber Y, Slovik E, Messersmith W, Hafler DA.

J Exp Med. 1997 May 5;185(9):1585-94.

14.

Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones.

Ausubel LJ, Kwan CK, Sette A, Kuchroo V, Hafler DA.

Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15317-22.

15.

Human T cell lymphotropic virus type I-induced T cell activation. Resistance to TGF-beta 1-induced suppression.

Höllsberg P, Ausubel LJ, Hafler DA.

J Immunol. 1994 Jul 15;153(2):566-73.

PMID:
8021495
16.

Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells.

Höllsberg P, Wucherpfennig KW, Ausubel LJ, Calvo V, Bierer BE, Hafler DA.

J Immunol. 1992 May 15;148(10):3256-63.

PMID:
1374452
Items per page

Supplemental Content

Loading ...
Support Center